Biotech Values

[maverick_1]

ONCE PH3 flying colors:CC 8:30 AM
http://www.benzinga.com/news/15/10/5886065/spark-therapeutics-announces-positive-top-line-results-from-pivotal-phase-3-trial?utm_campaign=partner_feed&utm_source=marketwatch.com&utm_medium=web_click&utm_content=ticker_page

Excerpts from above:

A summary of top-line efficacy results follows:

Primary outcome (ITT)
Mobility test (MT) change score, bilateral p = 0.001
Secondary outcomes (ITT)
FST, averaged over both eyes p < 0.001
MT change score, first injected eye p = 0.001
Visual acuity, averaged over both eyes p = 0.17

"This is a watershed moment in the long-time pursuit of innovative gene therapy solutions for a range of blinding retinal degenerative diseases," said Gordon Gund, chairman of the Foundation Fighting Blindness. "Spark, The Children's Hospital of Philadelphia, the Foundation Fighting Blindness and a long list of collaborators in the non-profit, academic and government sectors are to be commended for diligently persevering over many years in their aim to realize the potential of gene therapy in the fight against blindness."